NETWORKING ENTRE A COVID-19 E DOENÇAS AUTOIMUNES: REVISÃO DE LITERATURA
DOI:
https://doi.org/10.47820/recima21.v3i10.2086Palavras-chave:
Autoanticorpos, COVID-19, Doença autoimuneResumo
Introdução: A COVID-19 é uma doença infecciosa causada pelo coronavírus-2 associado à síndrome respiratória aguda grave (SARS-CoV-2). Embora a maioria dos indivíduos infectados sejam assintomáticos, uma proporção de pacientes com COVID-19 desenvolve doença grave com lesões em múltiplos órgãos. Objetivo: O presente estudo teve como objetivo correlacionar as doenças autoimunes com os mecanismos desencadeados pela infecção do SARS-CoV-2. Metodologia: Para este estudo, as bases de dados Center for Biotechnology Information (PubMed) e a biblioteca eletrônica Scientific Eletronic Library Online (SciELO), foram utilizadas. Como critério de inclusão foram selecionados artigos decorrentes da correlação das doenças autoimunes com a COVID-19. Desenvolvimento: Estudos elucidaram que o SARS-CoV-2 pode perturbar a autotolerância e desencadear respostas imunes por meio da reatividade cruzada com as células hospedeiras, culminando na produção de autoanticorpos, e consequentemente, no desenvolvimento de doenças autoimunes. No entanto, o risco de infecção e o prognóstico da COVID-19 em pacientes com doenças autoimunes permanece controverso, sendo necessários mais estudos para compreender a complexidade da correlação entre o vírus e o desencadeamento dessas doenças. Conclusão: É de fundamental importância a compreensão dos mecanismos imunológicos envolvidos, podendo abrir novos caminhos para a concepção de terapias eficazes.
Downloads
Referências
ANGILERI, F., et al. Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19?. British journal of haematology, 190(2), e92–e93, 2020.
BENUCCI, M., DAMIANI, A., INFANTINO, M., MANFREDI, M., & QUARTUCCIO, L. Old and new antirheumatic drugs for the treatment of COVID-19. Joint bone spine, 87(3), pp. 195–197, 2020.
BLANCO-MELO, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell, 181(5), pp. 1036–1045.e9, 2020.
BRUCE, I. N. et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the rheumatic diseases, 74(9), pp. 1706–1713, 2015.
CHANNAPPANAVAR, R. et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell host & microbe, 19(2), pp. 181–193, 2016.
CIAFFI, J., MELICONI, R., RUSCITTI, P., BERARDICURTI, O., GIACOMELLI, R., & URSINI, F. Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. BMC rheumatology, 4, p. 65, 2020.
DAHM, T., RUDOLPH, H., SCHWERK, CH., SCHROTEN, H. & TENENBAUM T. Neuroinvasion and Inflammation in Viral Central Nervous System Infections. Mediators of inflammation, 2016, 8562805, 2016.
DALAKAS, M. C. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurology(R) neuroimmunology & neuroinflammation, 7(5), e781, 2020.
DHORIA, V., et al. Rheumatic disease. Bull Hist Med; 14, pp. 123-6, 2020.
EHRENFELD, M., et al. Covid-19 and autoimmunity. Elsevier Public Health Emergency Collection, 19(8), 102597, 2020.
FAVA, A., & PETRI, M. Systemic Lupus Erythematosus: Diagnosis and Clinical Management. Journal of autoimmunity, 96, pp. 1-13, 2020.
FERNANDEZ-GUTIERREZ, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Annals of rheumatic diseases, 79(9), pp. 1170-1173, 2020.
FERNANDEZ-RUIZ, R., PAREDES, J. L., & NIEWOLD, T. B. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Translational research : the journal of laboratory and clinical medicine, 232, pp. 13–36, 2021.
GALEOTTI, C., & BAYRY, J. Autoimmune and inflammatory diseases following COVID-19. Nature reviews. Rheumatology, 16(8), 413–414, 2020.
GEHRS, B. C. & FRIEDBERG, R. C. Autoimmune hemolytic anemia. American Journal of Hematology, v. 69, pp. 258-271, 2002.
GIGLI, G. L., et al. HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(12), pp. 3391–3394, 2020.
HADJADJ, J., ET al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science, 369(6504), pp. 718–724, 2020.
HALPERT, G., & SHOENFELD, Y. SARS-CoV-2, the autoimmune virus. Autoimmunity reviews, 19(12), p. 102695, 2020.
JACOBS, J., & EICHBAUM, Q. COVID-19 associated with severe autoimmune hemolytic anemia. Transfusion, 61(2), pp. 635–640, 2021.
JIN H, et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc Neurol, 5(2), pp. 146-51, 2020.
KIRIAKIDOU, M., & CHING, C. L. Systemic Lupus Erythematosus. Annals of internal medicine, 172(11), ITC81–ITC96, 2020.
LAKOTA, K., et al. COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases. Frontiers in immunology, 11, 611318, 2021.
LAZARIAN, G., et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. British journal of haematology, 190(1), pp. 29–31, 2020.
LIU, Y., SAWALHA, A. H., & LU, Q. COVID-19 and autoimmune diseases. Current opinion in rheumatology, 33(2), pp. 155–162, 2021.
MARES, J., & HARTUNG, H. P. Multiple sclerosis and COVID-19. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 164(3), 217–225, 2020.
MASLOV, D. V., SIMENSON, V., JAIN, S., & BADARI, A. COVID-19 and Cold Agglutinin Hemolytic Anemia. TH open: companion journal to thrombosis and haemostasis, 4(3), e175–e177, 2020.
MATUCCI-CERINIC, M., HUGHES, M., TALIANI, G., & KAHALEH, B. Similarities between COVID-19 and systemic sclerosis early vasculopathy: A "viral" challenge for future research in scleroderma. Autoimmunity reviews, 20(10), 102899, 2021.
NICHOLAS, R., & RASHID, W. Multiple sclerosis. American family physician, 87(10), 712–714, 2013.
PASCOLINI, S. et al. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful?. Clinical and translational science, 14(2), pp. 502–508, 2021.
PICCHIANTI DIAMANTI, A., ROSADO, M. M., PIOLI, C., SESTI, G., & LAGANÀ, B. Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. International journal of molecular sciences, 21(9), p. 3330, 2020.
POLLARD, C. A., MORRAN, M. P., & NESTOR-KALINOSKI, A. L. The COVID-19 pandemic: a global health crisis. Physiological genomics, 52(11), pp. 549–557, 2020.
PONTILLO, A., et al. Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity, 45(4), pp. 271–278, 2012.
SACCHI, M. C. et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clinical and translational Science, 14(3), pp. 898-907, 2021.
SHAH, S., et al. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. Rheumatology international, 40(10), pp. 1539–1554, 2020.
VALK, S. J, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database of Systematic Reviews, 5, pp 5, 2020.
VITA, R., et al. The immune epitope database (IEDB) 3.0. Nucleic acids research, 43(Database issue), D405–D412, 2015.
WILLISON, H. J., JACOBS, B. C. & DOORN, P. A VAN. Guillain-Barré syndrome. The Lancet, 388 (10045), pp. 717-727, 2016.
ZUBERBÜHLER, P., et al. Guillain-Barre syndrome associated to COVID-19 infection: a review of published case reports. Síndrome de Guillain-Barré asociado a infección por COVID-19: revisión de casos publicados. Revista de neurologia, 72(6), 203–212, 2021.
Downloads
Publicado
Como Citar
Edição
Secção
Categorias
Licença
Direitos de Autor (c) 2022 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
